Clinical trials: Behavioural Disorder
Alcoholism
To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers
A total of at least 48 healthy subjects with a history of social drinking will be recruited into this single-centre, randomized, double-blind, cross-over study.
- Trial name
- NCT01738867
- Testing
- GSK1521498, Naltrexone (NTX)
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Attention Deficit Disorder With Hyperactivity
CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults
The purpose of this pilot study is to evaluate the safety, tolerability and potential effectiveness of CONCERTA® (methylphenidate hydrochloride extended-release tablets), a central nervous system (CNS) stimulant for the…
- Trial name
- NCT00246207
- Testing
- CONCERTA (OROS methylphenidate hydrochloride)
- Volunteers
- 32 people
- Sponsor
- Janssen-Ortho Inc., Canada
Attention Deficit Hyperactivity Disorder
Cognitive ADHD Videogame Exploratory Study
A study in ADHD and neuro-typical children to assess EVO game play over 29 days.
- Trial name
- CAVES (NCT01943539)
- Testing
- Neuro-typical controls and ADHD will receive EVO game play.
- Where
- 2 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Akili Interactive Labs, Inc.
Cerebrovascular Accident, Transient Ischemic Attack
Safety Study of Atomoxetine and Cerebrovascular Outcomes
Using a proprietary insurance health claims database, Eli Lilly and Company has contracted with an external party to conduct a retrospective cohort study of health claims for the time period from 1 January 2003 through 31…
- Conditions
- Cerebrovascular Accident, Transient Ischemic Attack, ADHD
- Trial name
- NCT00634439
- Testing
- atomoxetine, Stimulants, No intervention (general population)
- Where
- United States
- Volunteers
- 72,000 people
- Sponsor
- Eli Lilly and Company
ADHD, Autism
Acceptability, Feasibility, and Development of an AI Driven, Multi-sensor, Non-invasive Digital Mental Health Platform in Children With ADHD and Emotional Symptoms
This is an observational study collecting data using a wearable to measure the biometric features in youth with Attention deficit hyperactivity disorder(ADHD) and Autism.
- Trial name
- NCT06311370
- Testing
- Observation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- MaxisHealth
Attention Deficit Disorder With Hyperactivity
Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD and Previously Participated in MTS Trials
This study will evaluate the long-term safety of MTS in the symptomatic treatment of children aged 6-12 diagnosed with ADHD
- Trial name
- NCT00151957
- Testing
- Methylphenidate Transdermal System
- Volunteers
- 450 people
- Sponsor
- Noven Therapeutics
Attention Deficit Hyperactivity Disorder (ADHD), Anxiety Disorders and Symptoms
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
The primary objective of this study was to evaluate the efficacy and safety of Mexidol® film-coated tablets (125 mg) compared to a placebo in children aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- MEGA (NCT06854601)
- Testing
- Mexidol
- Where
- 14 sites in Russia
- Volunteers
- 333 people
- Sponsor
- Pharmasoft
Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
The purpose of this study is to evaluate the efficacy and safety of SHP465 at 6.25 mg in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6-12 years.
- Trial name
- NCT03325881
- Testing
- SHP465
- Where
- 41 sites in United States
- Volunteers
- 89 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Safety Study in Outpatient Japanese Children With ADHD
Evaluate the safety and efficacy of atomoxetine in Japanese pediatric patients with ADHD.
- Trial name
- NCT00485628
- Testing
- Atomoxetine Hydrochloride
- Where
- Japan
- Volunteers
- 37 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
This study evaluated the long-term safety and tolerability of centanafadine sustained-release (SR) tablets, administered twice daily (BID) in the treatment of adults with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT03605849
- Testing
- Centanafadine SR
- Where
- United States
- Volunteers
- 662 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention-Deficit/Hyperactivity Disorder (ADHD)
Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
This open label, flexible-dose study evaluating the safety and efficacy of SPN-812 administered with psychostimulants in children and adolescents (6 to 17 years of age) with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- ADHD (NCT04786990)
- Testing
- SPN-812
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 96 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children
Purpose of the study: evaluate the efficacy and safety of Prospekta in the treatment of attention deficit/hyperactivity disorder in children.
- Trial name
- NCT04569357
- Testing
- Prospekta
- Where
- 31 sites in Russia
- Volunteers
- 363 people
- Sponsor
- Materia Medica Holding
Attention Deficit Hyperactivity Disorder
Assessing Mobile Apps for Adult ADHD
The purpose of this clinical trial is to evaluate the effects of mobile app digital therapies on cognitive function and symptoms in adults diagnosed with ADHD.
- Trial name
- NCT06256003
- Testing
- UC-A, UC-N
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Think Now Incorporated
Attention Deficit Hyperactivity Disorder, Healthy
The Effects of EPA/DHA Supplementation on Cognitive Control in Children With ADHD
Forty children with and 40 children without Attention deficit Hyperactivity Disorder (ADHD) receive Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) or placebo via a dietary intervention.
- Trial name
- NCT01554462
- Testing
- Eicosapentaenoic acid / Docosahexaenoic acid
- Where
- Netherlands
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Attention Deficit Disorder With Hyperactivity
Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine whether CLONICEL® (clonidine HCl sustained release) is a safe and effective treatment for children and adolescents with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT00556959
- Testing
- high dose clonidine HCl sustained release, low dose clonidine HCl sustained release
- Where
- 13 sites in United States
- Volunteers
- 236 people
- Sponsor
- Addrenex Pharmaceuticals, Inc.
Attention Deficit/Hyperactivity Disorder
An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD
This is a multicenter, dose-optimized, randomized, double-blind, placebo controlled, efficacy and safety study with Azstarys® in children 4 to 12 years of age with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- KP415P01 (NCT05685732)
- Testing
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
- Where
- 20 sites in United States
- Volunteers
- 246 people
- Sponsor
- Corium, Inc.
Attention Deficit Hyperactivity Disorder
Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the efficacy, safety and to assess the impact of the treatment on quality of life of long-acting methylphenidate in adult participants with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00783835
- Testing
- Long-Acting Methylphenidate
- Where
- 5 sites in Brazil
- Volunteers
- 60 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Attention Deficit Hyperactivity Disorder (ADHD)
Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD.
2-week open-label safety, tolerability and pharmacokinetic study of methylphenidate HCl ERCT in 4-5 year old children with ADHD.
- Trial name
- NCT03546400
- Testing
- methylphenidate HCl ERCT
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder
Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD
The purpose of this study is to assess changes in ADHD symptoms and tolerability of medication in children and adolescents switching from a stimulant to atomoxetine.
- Trial name
- NCT00485875
- Testing
- Atomoxetine Hydrochloride
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder
A single arm, open-label, phase 3 multicenter study to evaluate the effectiveness and tolerability of atomoxetine (given once daily, target dose 1.2 mg/kg/day), as perceived by patients, parents and physicians, and its impact on…
- Trial name
- NCT00191516
- Testing
- Atomoxetine
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Eli Lilly and Company